First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
- DOI
- 10.3389/fonc.2024.1376551
- Published
- 2024
- Container
- Frontiers in oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3389/fonc.2024.1376551,
title = {First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.},
author = {Shimizu T and Powderly J and Abdul Razak A and LoRusso P and Miller KD and Kao S and Kongpachith S and Tribouley C and Graham M and Stoll B and Patel M and Sahtout M and Blaney M and Leibman R and Golan T and Tolcher A},
year = {2024},
journal = {Frontiers in oncology},
doi = {10.3389/fonc.2024.1376551},
url = {https://doi.org/10.3389/fonc.2024.1376551}
}RIS
TY - JOUR TI - First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors. AU - Shimizu T AU - Powderly J AU - Abdul Razak A AU - LoRusso P AU - Miller KD AU - Kao S AU - Kongpachith S AU - Tribouley C AU - Graham M AU - Stoll B AU - Patel M AU - Sahtout M AU - Blaney M AU - Leibman R AU - Golan T AU - Tolcher A PY - 2024 JO - Frontiers in oncology DO - 10.3389/fonc.2024.1376551 UR - https://doi.org/10.3389/fonc.2024.1376551 ER -
APA
T, S., J, P., A, A. R., P, L., KD, M., S, K., S, K., C, T., M, G., B, S., M, P., M, S., M, B., R, L., T, G., & A, T. (2024). First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.. Frontiers in oncology. https://doi.org/10.3389/fonc.2024.1376551
Source records
- pubmed · retrieved 2026-09-27T00:35:25.426Z